Piramal Pharma Limited
NSE: PPLPHARMA BSE: PPLPHARMA
Prev Close
154.68
Open Price
153.86
Volume
1,885,030
Today Low / High
151 / 158.62
52 WK Low / High
148.31 / 240.95
Range
147 - 162
Prev Close
154.55
Open Price
153.05
Volume
74,189
Today Low / High
151.3 / 158.65
52 WK Low / High
148.3 / 241
Range
145 - 160
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 154.68 (target range: 147 - 162), reflecting a change of -1.29 (0.6441%). On the BSE, it is listed at 152.85 (target range: 145 - 160), showing a change of -1.7 (-1.09997%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Piramal Pharma Limited Graph
Piramal Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Piramal Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 154.68, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 152.85 | 154.38 | 138.94 - 169.82 |
| 155.91 | 124.73 - 187.09 | ||
| 157.44 | 110.20 - 204.67 | ||
| Bearish Scenario | 152.85 | 151.32 | 136.19 - 166.45 |
| 149.79 | 119.83 - 179.75 | ||
| 148.26 | 103.79 - 192.74 |
Overview of Piramal Pharma Limited
ISIN
INE0DK501011
Industry
Biotechnology
Vol.Avg
3,435,767
Market Cap
204,698,467,266
Last Dividend
0.14
Official Website
IPO Date
2022-10-19
DCF Diff
268.84
DCF
-114
Financial Ratios Every Investor Needs
Stock Dividend of PPLPHARMA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-16 | July 16, 25 | 0.14 | 0.14 | 2025-07-16 | 2025-08-29 | |
| 2024-07-12 | July 12, 24 | 0.11 | 0.11 | 2024-07-12 | 2024-08-25 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 9,151.18 Cr | 3,231.65 Cr | 5,919.53 Cr | 0.6469 | 0.00 Cr | 2,340.38 Cr | 3,612.06 Cr | 91.13 Cr | 0.69 | 1,404.01 Cr | 0.0100 |
| 2024-03-31 | 8,171.16 Cr | 3,261.71 Cr | 4,909.45 Cr | 0.6008 | 100.67 Cr | 262.75 Cr | 519.75 Cr | 17.82 Cr | 0.14 | 1,366.81 Cr | 0.0022 |
| 2023-03-31 | 7,081.55 Cr | 5,983.52 Cr | 1,098.03 Cr | 0.1551 | 86.36 Cr | 231.69 Cr | -35.98 Cr | -186.46 Cr | -1.54 | 846.35 Cr | -0.0263 |
| 2022-03-31 | 6,559.10 Cr | 5,178.79 Cr | 1,380.31 Cr | 0.2104 | 128.34 Cr | 191.21 Cr | 373.64 Cr | 375.96 Cr | 3.11 | 1,259.94 Cr | 0.0573 |
| 2021-03-31 | 5,886.78 Cr | 2,073.55 Cr | 3,813.22 Cr | 0.6478 | 69.14 Cr | 53.85 Cr | 2,245.54 Cr | 571.50 Cr | 4.70 | 1,296.99 Cr | 0.0971 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 501.46 Cr | 15,677.59 Cr | 7,552.12 Cr | 8,125.4700 Cr | 4,856.47 Cr | 4,355.01 Cr | 2,312.70 Cr | 5,023.49 Cr | 0.00 Cr | 175.61 Cr | 271.09 Cr | 3,766.2700 Cr |
| 2024-03-31 | 356.82 Cr | 15,311.81 Cr | 7,400.44 Cr | 7,911.3700 Cr | 4,710.16 Cr | 4,353.34 Cr | 2,175.88 Cr | 4,815.96 Cr | 343.62 Cr | 167.90 Cr | 240.26 Cr | 4,369.3000 Cr |
| 2023-03-31 | 195.59 Cr | 14,522.56 Cr | 7,749.06 Cr | 6,773.5000 Cr | 5,637.08 Cr | 5,441.49 Cr | 1,681.37 Cr | 4,441.44 Cr | 201.13 Cr | 175.58 Cr | 211.87 Cr | 3,843.0500 Cr |
| 2022-03-31 | 228.10 Cr | 12,797.04 Cr | 6,100.44 Cr | 6,696.6000 Cr | 4,127.92 Cr | 3,899.82 Cr | 1,388.80 Cr | 3,715.74 Cr | 185.19 Cr | 150.47 Cr | 340.91 Cr | 3,033.3400 Cr |
| 2021-03-31 | 146.73 Cr | 5,756.67 Cr | 1,656.05 Cr | 4,100.6200 Cr | 174.26 Cr | 27.53 Cr | 420.88 Cr | 3,166.27 Cr | 0.00 Cr | 0.00 Cr | 122.67 Cr | 1,471.6700 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 892.3000 Cr | -477.4600 Cr | -440.8300 Cr | 227.9200 Cr | -36.8700 Cr | 182.3200 Cr | -664.3800 Cr | 91.1300 Cr | 48.7100 Cr | -14.4700 Cr | -197.1200 Cr |
| 2024-03-31 | 1,004.5400 Cr | -434.0100 Cr | -422.3600 Cr | 292.5000 Cr | 165.9600 Cr | 219.1900 Cr | -712.0400 Cr | 17.8200 Cr | -971.5300 Cr | 0.0000 Cr | -531.7500 Cr |
| 2023-03-31 | 483.8900 Cr | -1,338.7800 Cr | 817.7900 Cr | -480.8600 Cr | -31.9500 Cr | 53.2300 Cr | -964.7500 Cr | -160.5600 Cr | 1,198.4200 Cr | -67.0000 Cr | -172.6400 Cr |
| 2022-03-31 | 766.4200 Cr | -1,812.1000 Cr | 794.1900 Cr | -123.0900 Cr | -176.7900 Cr | 85.1800 Cr | -889.5100 Cr | 436.7000 Cr | 1,019.1300 Cr | -50.0000 Cr | -60.3300 Cr |
| 2021-03-31 | 34.7200 Cr | -4,382.8900 Cr | 4,494.1600 Cr | -23.3900 Cr | 145.9900 Cr | 146.7300 Cr | -58.1100 Cr | 349.1100 Cr | 90.3800 Cr | 0.0000 Cr | 95.3600 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 2,139.87 Cr | 1,598.90 Cr | 540.97 Cr | 0.2528 | -17.01 Cr | -136.19 Cr | -1.03 | 197.86 Cr | -0.0636 |
| 2025-09-30 | 2,043.72 Cr | 1,516.80 Cr | 526.92 Cr | 0.2578 | -44.15 Cr | -99.22 Cr | -0.75 | 224.29 Cr | -0.0485 |
| 2025-06-30 | 1,933.71 Cr | 694.05 Cr | 1,239.66 Cr | 0.6411 | -90.58 Cr | -81.70 Cr | -0.62 | 204.41 Cr | -0.0423 |
| 2025-03-31 | 2,754.07 Cr | -561.01 Cr | 3,315.08 Cr | 1.2037 | 3,301.80 Cr | 153.50 Cr | 1.16 | 512.11 Cr | 0.0557 |
| 2024-12-31 | 2,204.22 Cr | 805.83 Cr | 1,398.39 Cr | 0.6344 | 140.93 Cr | 3.68 Cr | 0.03 | 366.92 Cr | 0.0017 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 521.58 Cr | 222.48 Cr | 744.06 Cr | 1,984.59 Cr | 2,742.83 Cr | 5,953.02 Cr | 5,221.86 Cr | 16,189.43 Cr | 8,115.64 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 408.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -8,125.47 Cr |
| 2025-03-31 | 501.46 Cr | 19.56 Cr | 521.02 Cr | 2,349.52 Cr | 2,312.70 Cr | 5,796.99 Cr | 5,023.49 Cr | 15,677.59 Cr | 7,552.12 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 408.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -7,907.17 Cr |
| 2024-09-30 | 398.01 Cr | 10.40 Cr | 408.41 Cr | 1,827.14 Cr | 2,447.43 Cr | 5,381.66 Cr | 4,918.75 Cr | 15,241.74 Cr | 7,334.57 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | -81.70 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 153.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 3.68 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 22.59 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -88.64 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2023-08-02 | August 02, 23 | 1023:1000 |
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹373.95 | ₹482,068,985,184.00 | ₹5,895,114.00 |
| Anthem Biosciences Ltd. | ANTHEM | ₹590.50 | ₹331,630,735,116.00 | ₹411,346.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹154.68 | ₹204,698,467,266.00 | ₹1,883,871.00 |
| Syngene International Limited | SYNGENE | ₹473.45 | ₹190,209,382,135.00 | ₹1,071,600.00 |
| Onesource Specialty Pharma Ltd. | ONESOURCE | ₹1,194.50 | ₹136,871,949,730.00 | ₹68,928.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,161.50 | ₹121,511,720,946.00 | ₹31,516.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹625.65 | ₹98,859,510,200.00 | ₹54,036.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹410.50 | ₹71,207,556,963.00 | ₹104,971.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹676.05 | ₹54,410,396,940.00 | ₹59,594.00 |
| Zota Health Care Limited | ZOTA | ₹1,288.50 | ₹39,083,625,968.00 | ₹17,266.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹217.01 | ₹34,023,499,446.00 | ₹69,660.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born: 1978
Gender: male
Year Born:
Gender: male
Year Born: 1974
Gender: male
Year Born: 1973
Gender: female
Year Born: 1980
Gender: female
Year Born:
Gender: female
Year Born:
Gender: Not Specified
Year Born: 1973
Gender: Not Specified
Year Born: 1964
FAQs about Piramal Pharma Limited
The CEO is Peter Daniel DeYoung.
The current price is ₹154.68.
The range is ₹148.31-240.95.
The market capitalization is ₹20,469.85 crores.
The dividend yield is 0.09%.
The P/E ratio is -124.92.
The company operates in the Healthcare sector.
Overview of Piramal Pharma Limited (ISIN: INE0DK501011) is a leading Biotechnology in India. With a market capitalization of ₹20,469.85 crores and an average daily volume of 3,435,767 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.14.